Kamal Mohammed, PhD

Kamal A. Mohammed, PhD
Research Associate Professor

Email: mkamal@medicine.ufl.edu

TEL: 352.376.1611, ext. 7446
Lab TEL: 352.376.1611, ext. 6491
FAX: 352.273.6172




PhD Osmania University, India Immunology

Research Interests:

  • Innate and adaptive immune defenses in pleuro-pulmonary infections
  • Toll-like receptor (TLR) signaling in pleural infections and asthma
  • Methicillin Resistant Staphylococcus aureus induced pleural/lung injury and barrier dysfunction
  • Tobacco Smoke induced airway remodeling and lung injury in COPD
  • Micro-RNA signaling in malignant pleural mesothelioma tumor growth

Professional Societies:

  • American Thoracic Society
  • American Federation for Medical Research
  • American Society for Pharmacology and Experimental Therapeutics
  • South East Thoracic Association

Research Grant Support:

  • Ongoing
  • VA Merit: Mechanisms of Pleural Fibrosis in Empyema. Principal Investigator, 2010-2016
  • Department of Defense: Epha2 -/- NK cell therapy against Malignant Pleural Mesothelioma. Co-Investigator (Principal Investigator: Nasreen Najmunnisa PhD). 2015-2017
  • UF-Gatorade
  • Completed
  • VA Merit: Mechanism of Development of Parapneumonic effusions. Principal Investigator, 2007-2010.
  • Florida Department of Health- Bankhead Coley Cancer Research program. Micro-RNA Based Novel Targeted Therapy for Malignant Pleural Mesothelioma. Co-Investigator (Principal Investigator: Nasreen Najmunnisa PhD). 2013-2015
  • Florida Department of Health James Ester King Research program. Co-Investigator (Principal Investigator: Jianrong Lu, PhD).2013-2015
  • A Novel Ubiquitin Ligase in Epithelial Maintenance against Tobacco Smoke and Lung Cancer Progression.
  • Florida Department of Health- James Ester King Research program. Eph-A2 signaling in Tobacco Smoke Induced Bronchial Airway Epithelial Injury. Co-Investigator (Principal Investigator: Nasreen Najmunnisa PhD). 2009-2012.
  • GlaxoSmithKline: Significance of SOCS3 in Airway Inflammation in COPD. Principal Investigator, 2009-2011.
  • National Institutes of Health: HO-1 and granuloma formation in TB Pleurisy, Co-Investigator (Principal Investigator: Veen Antony, MD), 2009-2011.
  • Florida Department of Health RC1 Intra-tumoral Gene Therapy (ITGT) in mouse model for lung cancer. Co-Investigator (Principal Investigator: Nasreen Najmunnisa, PhD) -2010-2012.
  • National Institutes of Health: Co-Investigator (Principal Investigator: Veena B Antony, MD) “Monocyte Recruitment in Pleuro-Pulmonary TB in AIDS” 2001-2006
  • University of Florida Division of Sponsored Research, Principal Investigator
  • “Pleural Mesothelial Cell Toll-Like Receptors in Empyema” 2004-2005

Honors and Awards:

  • 2015 -Outstanding Researcher Award, University of Florida College of Medicine, Gainesville, FL.
  • 2014 – Mid Career Outstanding Researcher Award, University of Florida College of Medicine, Gainesville, FL.
  • 2013 – Mid Career Outstanding Researcher Award, University of Florida College of Medicine, Gainesville, FL.
  • 2009 –Excellence in Research Award, University of Florida College of Medicine, Gainesville, FL-32610.
  • 1997 –Young Trainee Investigator Award. American Federation of Clinical Research/Central Society for Clinical Research-USA.
  • 1992 –Fogarty International Travel Award. National Institutes of Health, Bethesda, USA.
  • 1995 –CSIR Young Investigator Travel Award. Department of Biotechnology and Council of Scientific and Industrial Research, Government of India.
  • 1994 –CSIR-Post Doctoral Fellowship -1994. Council of Scientific and Industrial Research, Government of India.

Publications (2004 onwards):

  • Nasreen N, Khodayari N, Sriram PS, Patel J, Mohammed KA. Tobacco Smoke induces Epithelial Barrier Dysfunction via Receptor EphA2 Signaling. Am J Physiol Cell Physiol. 2014 Jun 15;306(12):C1154-66. doi: 10.1152/ajpcell.00415.2012. Epub 2014 Apr 9.
  • Nasreen N, Gonzalves L, Sriram PS, Mohammed KA. Fluticasone furoate is more effective than mometasone furoate in restoring tobacco smoke inhibited SOCS-3 expression in airway epithelial cells. Immunopharmacol. 2014 Mar; 19(1):153-60.doi10.1016/j.intimp.2013.12.029. Epub 2014 Jan 13.
  • Nasreen N., Khodayari N., and Mohammed K.A. Advances in Malignant Pleural Mesothelioma therapy: Targeting EphA2 a Novel Approach. Am J Cancer Research Am J Cancer Res 2012; 2(2):222-234.
  • Nasreen, N, Khodayari N., Bhagyalaxmi Sukka-Ganesh, Peruvemba S., and Kamal A. Mohammed. Fluticasone Propionate and Salmeterol Combination Induces SOCS-3 Expression in Airway Epithelial Cells. International Journal of Immuno-pharmacology, 2012 Jan;12(1):217-25. doi: 10.1016/j.intimp.2011.11.014.
  • Mohammed, K.A., Xiaohong Wang, Antony, VB, and Nasreen N. Silencing receptor EphA2 Induces Apoptosis and attenuate tumor growth in Malignant Mesothelioma. Am J Cancer Research, 2011; 1(3): 419-431. Epub 2011 Feb 10.
  • Tajamul Hussain, Nasreen, N., Lai, Y., Bellew, B. F., Antony, V. B., Mohammed, K.A. Innate Immune Responses in Murine Pleural Mesothelial Cells: TLR2 Dependent Induction of -defensin-2 by Staphylococcal Peptidoglycan. Am J Physiol Cell and Mol Physiol., Sep; 295(3):L461-L470, 2008.
  • Kamal A. Mohammed*, Nasreen N, Robert S. Tepper, and Veena B. Antony. Inhibition of P44/42 MAPK Ameliorates Cyclical Stretch induced PlGF release in Bronchial Airway Epithelial Cells.  Am J Physiol Lung Cell Mol Physiol. 292(2):L559-L566, 2007 (*Corresponding author).
  • Kamal A. Mohammed*, Nasreen N, and Antony V. B.  Staphylococcus aureus Induces Differential Expression of C-fos, C-jun and Mediates Apoptosis in Pleural Mesothelial Cells. Lung. 185(6):355-365, 2007 (*Corresponding author).
  • Kamal A. Mohammed, Najmunnisa Nasreen, Joyce Hardwick, Robert D. Van Horn, Kerry L. Sanders, And Veena B. Antony. Mycobacteria Induces Pleural Mesothelial Permeability by down-regulating beta-catenin Expression. Lung, 181(2):57-66, 2003.
  • Ajay B. Antony, Robert S. Tepper, Mohammed K.A., Cockroach Extract Allergen Induces Permeability Change in Human Bronchial Airway Epithelial Cells. Allergy Clin Immunol. 110(4):589-595, 2002.
  • Kamal A. Mohammed, Nasreen N, Joyce Hardwick, Carolyn S. Logie, Carolyn E. Patterson, And Veena B. Antony. Bacterial Induction of Pleural Mesothelial Monolayer Barrier Dysfunction. Am J Physiol – Lung Cell Mol Physiol. 281:L119-L125, 2001.
  • Kamal A. Mohammed, Nasreen N., Ward M.J. and Antony V.B. Induction of Acute Pleural Inflammation by Staphylococcus aureus: I. CD4+ T cells Play a Critical Role in Experimental Empyema. Infec. Dis. 181(5):1693-1699, 2000.
  • Kamal A. Mohammed, Nasreen N., Ward M.J., and Antony V.B. Helper T-cell type 1 and 2 Cytokines Regulate C-C Chemokine Expression in Mesothelial Cells. J. Respir. Crit. Care Med. 159: 1653-1659, 1999.
  • Kamal A. Mohammed, Nasreen, M.J. Ward, Panadero F.R. and V.B. Antony. Mycobacterium Mediated Chemokine Expression in Pleural Mesothelial Cells: Role of C-C Chemokines in Tuberculous Pleurisy. J. Infec. Dis. 178: 1450-1456, 1998.

Inventions and Patents

  • Patent number: EEC-9402989; UF #11831.
    • Year of patent: 2005.
    • Title: Novel Living Tissue Culture Stylus for the Interrogation of Bioactive Nanostructures
  • Patent Number: UF#-15762.
    • Year of patent: 2015.
    • Title: Novel Anionic Polyhedral Oligomeric Silsesquioxane Based Lipoplex for Gene Delivery (Pending).

Please click here for a list of Dr. Mohammed’s industry relationships.